KATHERINE HOLDWICK: Open Payments
NPI 1912400136 · LENOX, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$487 in 24 payments from 15 companies in 2025. Trend: 2023 $390 · 2024 $568 · 2025 $487
Food & beverage: $487
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 3 | $76 |
| AstraZeneca Pharmaceuticals LP | 3 | $60 |
| ABBVIE INC. | 2 | $59 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $38 |
| GlaxoSmithKline, LLC. | 2 | $37 |
| Novo Nordisk Inc | 2 | $34 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $32 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| PFIZER INC. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
Products named: REXULTI, UBRELVY, XIFAXAN, CAPLYTA, FANAPT, TRELEGY ELLIPTA, BREZTRI, NURTEC ODT.
Industry payments across MI — which companies pay providers there.
